Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472855 | 0.94 | PTGER1 (0.44) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6471345 | 0.93 | MAOB (0.43) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6473312 | 0.92 | MAPK14 (0.54) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6473202 | 0.91 | MAPK14 (0.49) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6532902 | 0.91 | PTGER1 (0.47) | MAPK14MAOBPTGER1 | |
| SCHEMBL6471760 | 0.91 | MAPK14 (0.53) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6473038 | 0.90 | MAPK14 (0.55) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6471398 | 0.90 | MAPK14 (0.49) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6471464 | 0.90 | MAPK14 (0.55) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6471427 | 0.90 | MAPK14 (0.46) | MAPK14PTGER1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |